Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapyloric Botox vs Pyloromyotomy During Esophagectomy
NCT06721520Phase 3Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of botulinum toxin type A in gastroparesis (2 arms), sponsored by Cleveland Clinic. Primary endpoint: Gastroparesis Cardinal Symptom Index total score at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT06721520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721520.